Status:
NOT_YET_RECRUITING
Effect of HFR-SUPRA in the Treatment of Multiple Myeloma-related Acute Kidney Injury
Lead Sponsor:
Peking Union Medical College Hospital
Collaborating Sponsors:
Bellco Hoxen Medical (Shanghai) Co., Ltd
Conditions:
Multiple Myeloma
Acute Kidney Injury
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
In patients with multiple myeloma-related acute kidney injury, compare the renal outcome of chemotherapy combined with HFR-SUPRA to chemotherapy combined with hemodialysis.
Detailed Description
In patients with multiple myeloma-related severe acute kidney injury, compare the renal outcome between patients receiving HFR-SUPRA and patients receiving hemodialysis. Both groups of patients receiv...
Eligibility Criteria
Inclusion
- 18 to 80 years old
- new onset of multiple myeloma
- acute kidney injury with eGFR \< 15 ml/min/1.73m2 and need hemodialysis
- biopsy-proven cast nephropathy or clinical diagnosis of cast nephropathy based on exclusion of other causes of acute kidney injury including post-renal obstruction, hypercalcaemia, amyloidosis, light-chain deposition disease, contrast media and drug nephropathy
- serum light chain \> 500 mg/L
Exclusion
- chronic kidney disease stage 3 to 5 (eGFR\< 60 ml/min/1.73m2 for at least 3 months)
- haemodynamics unstability
- active bleeding
- cardiovascular and cerebrovascular events in the last month
- other malignant tumor
- conditions not suitable to participate in the study, such as bad compliance
Key Trial Info
Start Date :
July 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2032
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT05429515
Start Date
July 1 2022
End Date
December 1 2032
Last Update
June 23 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.